Highlights:

• TLX jumped 6.40%, ranking among the ASX 200’s top five opening gainers.
• US$1.65 billion ITM deal could materially expand Telix’s isotope manufacturing and therapy pipeline.
• ASX waivers provide Telix with greater flexibility on share issuance, while shareholder approval remains the next key milestone.

Telix Leads Opening Gains

Telix Pharmaceuticals Limited (ASX: TLX) returned to market focus after unveiling its proposed combination with ITM Isotope Technologies Munich SE on 21 September 2026, followed by an ASX Listing Rule waiver announcement on 22 September 2026. The first release detailed the transaction, while the latest update addressed the timing framework for issuing merger-related shares. At the opening bell, Telix was among the S&P/ASX 200’s top five gainers, with a current market price (CMP) of AU$16.770, up approximately 6.40%.

ITM Deal Expands Telix’s Global Reach

As outlined on 21 September, Telix intends to purchase all outstanding ITM shares in a transaction carrying an upfront value of US$1.65 billion on a cash-free and debt-free basis. The proposed consideration comprises about US$1.25 billion in Telix shares, the assumption of US$302 million in net debt, and US$96 million associated with management equity rollover and transaction-related expenses. Up to another US$700 million could become payable if specified ITM-11 regulatory and sales milestones are reached.

• ITM generated US$273 million in 2025 revenue after roughly 40% CAGR from 2021–2025.
• Its global radioisotope production and distribution operations reach customers across more than 65 countries.
• ITM-11 has completed Phase 3 development for its initial GEP-NET indication.

ASX Waivers Advance Deal

On 22 September, Telix confirmed ASX had granted waivers from Listing Rule 7.3.4, allowing transaction-related shares to be issued beyond the usual three-month period following shareholder approval. This accommodates the longer timetable associated with closing requirements and future milestones. The waivers carry specific issuance deadlines, disclosure requirements and safeguards around potential dilution.

Shareholders are expected to vote on the proposed transaction during Telix’s extraordinary general meeting scheduled for November 2026.

Execution Moves into Focus

The combination could give Telix greater control over isotope supply, broaden its therapeutic pipeline and expand its global manufacturing footprint. Management estimates the combined business could exceed US$1.3 billion in 2026 pro forma revenue and other income, with ITM expected to contribute positively to group EBITDA from 2027 onward.

Attention now shifts to shareholder approval, transaction completion, integration execution and ITM-11’s regulatory progress. These milestones will be central to determining whether the proposed scale and operational synergies translate into sustainable earnings growth.

Note- All data presented is based on information available at the time of writing.

Disclaimer for Kapitales Research

The materials provided by Kapitales Research, including articles, news, data, reports, opinions, images, charts, and videos ("Content"), are intended for personal, non-commercial use only. The primary goal of this Content is to educate and inform readers. This Content is not meant to offer financial advice, nor does it include any recommendation or opinion that should be relied upon for making financial decisions. Certain Content on this platform may be sponsored or unsponsored, but it does not serve as a solicitation or endorsement to buy, sell, or hold any securities, nor does it encourage any specific investment activities. Kapitales Research is not authorized to provide investment advice, and we strongly advise users to seek guidance from a qualified financial professional, such as a financial advisor or stockbroker, before making any investment choices. Kapitales Research disclaims all liability for any direct, indirect, incidental, or consequential damages arising from the use of the Content, which is provided without any warranties. The opinions expressed by contributors or guests are their own and do not necessarily reflect the views of Kapitales Research. Media such as images or music used on this platform are either owned by Kapitales Research, sourced through paid subscriptions, or believed to be in the public domain. We have made reasonable efforts to credit sources where appropriate. Kapitales Research does not claim ownership of any third-party media unless explicitly stated otherwise.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.Disclosure: The information mentioned above has been sourced from the company reports and a third-party database, i.e. Koyfin. Investors are advised to use strict stop-loss to protect their investments in case of any unfavorable/uncertain market events.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au